Lung cancers are classified by type: small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC). SCLCs are associated with smoking and metastasize very early. Non-smokers usually present with NSCLC. NSCLC are further subdivided into squamous cell carcinomas, adenocarcinomas, and large cell carcinomas. Since both SCLC and NSCLC are usually diagnosed after the disease has spread beyond the primary site, the overall survival rates for lung cancers are poor. To breathe new life into your lung cancer research, ATCC provides numerous lung cancer cell lines, human primary cells, and hTERT-immortalized cell lines. To further increase the throughput of your lung cancer experiments, ATCC has organized lung cancer cell lines into tumor cell panels.
ATCC retains a vast collection of cell lines derived from the lung or from the head and neck cells of multiple species. These cells are ideal models for cancer as they were derived from tumors isolated from patients or animals. ATCC also uses CRISPR/Cas9 technology to create isogenic cell lines. The EML4-ALK Fusion-A549 Isogenic Cell Line is the first cell line derived from the parental non-small cell lung cancer cell line A549.
Lung Cancer Cell Lines
Physiologically Relevant Controls
All experiments should include physiologically relevant controls. ATCC provides both primary and hTERT-immortalized bronchial epithelial cells and small airway cells that may be used side-by-side with NSCLC or SCLC cells as normal controls. The primary and hTERT-immortalized cells may also be used to create 3D cell culture models to better represent an in vivo environment ex vivo.
hTERT Immortalized Cells
The ATCC Lung Tumor Cell Panel combines authenticated, well-characterized cell lines with mutation data from the Sanger Institute Catalogue of Somatic Mutations in Cancer (COSMIC) to create powerful tools for cancer research and drug discovery. ATCC Tumor Cell Panels provide subtype-specific collections of cells to improve the pace of your research.
Lung Tumor Cell Panels